SEC Form 4 · accession 0001140361-16-068345
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
May 31, 2016
Accepted (ET)
Jun 2, 2016 · 6:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 31, 2016 | M | 16,896 | $39.06 | A | 71,235 | D | |
| Common StockF1,F2 | May 31, 2016 | S | 16,896 | $90.00 | D | 54,339 | D | |
| Common StockF1,F2 | May 31, 2016 | S | 3,945 | $89.35 | D | 50,394 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) Common StockF3 | $39.06 | May 31, 2016 | M | 16,896 | A | Nov 29, 2012 | May 28, 2022 | Common Stock | 16,896 | 2,604 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 9, 2016.
- F2All shares were sold at the same price.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.